Nuveen LLC Buys Shares of 314,275 Heron Therapeutics, Inc. $HRTX

Nuveen LLC bought a new stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 314,275 shares of the biotechnology company’s stock, valued at approximately $691,000. Nuveen LLC owned 0.21% of Heron Therapeutics at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Invesco Ltd. lifted its position in Heron Therapeutics by 67.6% during the 1st quarter. Invesco Ltd. now owns 119,662 shares of the biotechnology company’s stock valued at $263,000 after purchasing an additional 48,263 shares during the period. Deutsche Bank AG lifted its position in Heron Therapeutics by 43.2% during the 1st quarter. Deutsche Bank AG now owns 85,610 shares of the biotechnology company’s stock valued at $188,000 after purchasing an additional 25,824 shares during the period. Headlands Technologies LLC lifted its position in Heron Therapeutics by 260.5% during the 1st quarter. Headlands Technologies LLC now owns 92,558 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 66,886 shares during the period. JW Asset Management LLC lifted its position in Heron Therapeutics by 2.0% during the 1st quarter. JW Asset Management LLC now owns 2,337,743 shares of the biotechnology company’s stock valued at $5,143,000 after purchasing an additional 45,325 shares during the period. Finally, Vanguard Group Inc. lifted its position in Heron Therapeutics by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 8,225,585 shares of the biotechnology company’s stock valued at $18,096,000 after purchasing an additional 67,976 shares during the period. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Adam Morgan purchased 1,766,546 shares of Heron Therapeutics stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $1.50 per share, with a total value of $2,649,819.00. Following the transaction, the director directly owned 8,753,290 shares in the company, valued at $13,129,935. The trade was a 25.28% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Rubric Capital Management Lp purchased 2,387,225 shares of Heron Therapeutics stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $1.50 per share, with a total value of $3,580,837.50. Following the transaction, the insider owned 29,100,728 shares in the company, valued at approximately $43,651,092. The trade was a 8.94% increase in their ownership of the stock. The disclosure for this purchase can be found here. 5.86% of the stock is currently owned by corporate insiders.

Heron Therapeutics Stock Performance

NASDAQ HRTX opened at $1.33 on Thursday. The business has a 50 day simple moving average of $1.75 and a 200 day simple moving average of $1.96. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $2.68. The stock has a market cap of $203.88 million, a price-to-earnings ratio of -66.50 and a beta of 1.22.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Friday, August 8th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The company had revenue of $37.20 million during the quarter, compared to analyst estimates of $38.08 million. Heron Therapeutics has set its FY 2025 guidance at EPS. On average, analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on HRTX. Zacks Research raised Heron Therapeutics to a “strong sell” rating in a research note on Tuesday, August 12th. HC Wainwright began coverage on Heron Therapeutics in a research note on Monday, June 9th. They issued a “buy” rating and a $6.00 price target for the company. Needham & Company LLC lowered their price target on Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Wall Street Zen cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.50.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.